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Although inhibition of the epidermal growth factor receptor is a plausible therapy for malignant gliomas that, in vitro, enhances
apoptosis, the results of clinical trials have been disappointing. The mammalian target of rapamycin (mTOR) is a serine/
threonine kinase that integrates starvation signals and generates adaptive responses that aim at the maintenance of energy
homeostasis. Antagonism of mTOR has been suggested as a strategy to augment the efficacy of epidermal growth factor
receptor inhibition by interfering with deregulated signalling cascades downstream of Akt. Here we compared effects of antag-
onism of mTOR utilizing rapamycin or a small hairpin RNA-mediated gene silencing to those of epidermal growth factor
receptor inhibition or combined inhibition of epidermal growth factor receptor and mTOR in human malignant glioma cells.
In contrast to epidermal growth factor receptor inhibition, mTOR antagonism neither induced cell death nor enhanced apoptosis
induced by CD95 ligand or chemotherapeutic drugs. However, mTOR inhibition mimicked the hypoxia-protective effects of
epidermal growth factor receptor inhibition by maintaining adenosine triphosphate levels. These in vitro experiments thus
challenge the current view of mTOR as a downstream target of Akt that mediates antiapoptotic stimuli. Under the conditions
of the tumour microenvironment, metabolic effects of inhibition of epidermal growth factor receptor, Akt and mTOR may
adversely affect outcome by protecting the hypoxic tumour cell fraction.
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Abbreviations: 4E-BP1 = eukaryotic translation initiation factor 4E binding protein 1; CD95L = CD95 ligand; EGFR = epidermal
growth factor receptor; eIF4E = eukaryotic translation initiation factor 4E; HIF-1 a= hypoxia inducible factor-1 a; LDH = lactate
dehydrogenase; mTOR = mammalian target of rapamycin; p42/44 MAPK = p42/44 mitogen-activated protein kinase;
PI3K = phosphatidyl-inositole-3-phosphate kinase; RPS6 = ribosomal protein S6; S6K1 = ribosomal protein S6 kinase 1;
shRNA = small hairpin RNA
Introduction
Patients with glioblastoma face a grim prognosis with a median
survival of 51 year in unselected cohorts (Ohgaki et al., 2004).
Novel therapeutic approaches are, therefore, urgently needed.
Targeting signalling downstream of activated growth factor
receptors is currently considered one of the most promising
approaches. Specifically, the epidermal growth factor receptor
(EGFR) is amplified or activated in the majority of primary
glioblastomas and can be regarded as one of the most plausible
targets for molecular therapy (Kleihues et al., 2000). EGFR signal-
ling sustains many key features of the neoplastic phenotype, e.g. it
enhances cell autonomous growth, invasion and angiogenesis and
confers protection from growth inhibitory and proapoptotic stimuli
(Mendelsohn, 2002; Steinbach and Weller, 2002).
Clinical trials with small molecule kinase inhibitors of the EGFR
in malignant glioma patients, however, have produced disappoint-
ing results (Van Den Bent et al., 2009). Insufficient suppression of
the intracellular signalling cascade downstream of EGFR has been
suggested as an important cause for the failure of EGFR inhibitors.
Phosphorylation of Akt, in particular, represents a negative
predictive marker for the response of malignant glioma patients
to EGFR inhibitors (Haas-Kogan et al., 2005). The serine/threonine
kinase mammalian target of rapamycin (mTOR) is a key mediator
of phosphatidyl-inositole-3-phosphate kinase (PI3K) and Akt sig-
nalling. It integrates growth-inhibitory signals such as deprivation
of glucose and amino acids, ATP depletion, hypoxia and lack of
growth factors (Wullschleger et al., 2006) in order to generate
adaptive cellular responses primarily by altering the translation of
specific proteins. Deregulated mTOR signalling sustains prolifer-
ation of malignant cells by antagonizing these physiological
starvation signals (Peng et al., 2002). It therefore appears plausible
that the commonly observed activation of mTOR signalling in
glioblastoma (Choe et al., 2003) contributes to the typical pattern
of glioblastoma pathology with necrotic cores and aggressive
growth at the tumour margins. The translational effects of
mTOR signalling are mediated by phosphorylation of its two
direct target molecules, eukaryotic translation initiation factor 4E
binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1
(S6K1), at specific sites. Phosphorylation of 4E-BP1 occurs
stepwise and relieves its repression of eukaryotic initiation factor
4E (eIF4E) (Hara et al., 1997), resulting in activation of translation
initiation. In this process, phosphorylation of the residues Thr37/
46 is the initial step in eukaryotic translation initiation factor 4E
binding protein 1phosphorylation. It is also a prerequisite for phos-
phorylation of residues Thr70 and Ser65, whose phosphorylation
alone is not sufficient to block binding to eukaryotic initiation
factor 4E (Gingras et al., 2001). The different phosphorylation
states of 4E binding protein 1 are evidenced by three differently
migrating bands in immunoblot analyses: (i) a fastest migrating
hypophosphorylated a band; (ii) a b band of intermediate mobility;
and (iii) a slowest migrating hyperphosphorylated g band. Thr37/
46 phosphorylated 4E-BP1 can be detected in all three bands and
is relatively insensitive to serum deprivation and mTOR inhibition.
However, the pattern of phosphorylated 4E-BP1 shifts to the
hypophosphorylated faster migrating bands following mTOR
inhibition (Brunn et al., 1997). Phosphorylation of S6K1 results
in activation of its kinase activity and phosphorylation of ribosomal
protein S6 (RPS6), which, among other proteins, regulates trans-
lation of ribosomal proteins and elongation factors (Hay and
Sonenberg, 2004). With the availability of rapamycin and related
drugs that specifically inhibit mTOR signalling, considerable
interest has been generated to investigate antagonism of mTOR
as an anti-glioma strategy (Hidalgo and Rowinsky, 2000; Huang
and Houghton, 2001). In preclinical models, mTOR inhibition has
been reported to result in apoptotic and non-apoptotic cell death
(Rao et al., 2005; Takeuchi et al., 2005), cell cycle arrest (Tanaka
et al., 2007) and decreased angiogenesis (Del Bufalo et al., 2006).
mTOR inhibition is particularly effective against some cell lines
with mutant PTEN (Neshat et al., 2001).
Augmentation of the efficacy of EGFR inhibition by mTOR
inhibition therefore appears plausible (Doherty et al., 2006;
Reardon et al., 2006). However, we have previously identified
an undesirable consequence of interference with EGFR function
that offers an alternative explanation for the poor clinical perfor-
mance of EGFR antagonistic strategies and may also adversely
affect the efficacy of mTOR inhibition. Altered cellular metabolism
and energy expenditure, which are enhanced by EGFR signalling,
are at the core of this phenomenon which results in the protection
of malignant glioma cells from hypoxia when EGFR is inhibited
(Steinbach et al., 2004, 2005). In these experiments, EGFR
inhibition and resistance towards hypoxia were associated with
decreased phosphorylation of the mTOR target ribosomal protein
S6. Given the physiological role of mTOR in the regulation of
metabolic demands, these results suggested that EGFR inhibition
confers protection against hypoxia in a mTOR-dependent fashion.
We report the results of a comprehensive analysis of
cell-autonomous effects of mTOR antagonism on CD95 ligand-,
chemotherapy- and hypoxia-induced cell death in human malig-
nant glioma cells employing rapamycin and hairpin RNA-mediated
gene suppression of mTOR (Brummelkamp et al., 2002) and a
comparison of mTOR inhibition with EGFR inhibition or combined
inhibition of mTOR and EGFR.
Materials and Methods
Reagents and cell lines
U0126, an inhibitor of MEK 1 and 2, the PI3K inhibitor LY294002,
Akt inhibitor VIII and EGF were purchased from Calbiochem
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(San Diego, CA, USA), the EGFR inhibitor PD153035 and the mTOR
inhibitor rapamycin from Tocris Cookson (Bristol, UK), erlotinib and
IGF-1 from Roche (Mannheim, Germany). Tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL) was purchased from
PeproTech (Rocky Hill, NJ, USA). LNT-229 (PTEN wildtype) and
U87MG (PTEN mutant) human malignant glioma cell lines have
been described (Ishii et al., 1999; Steinbach et al., 2003, 2004). The
generation of primary cell cultures has also been previously described
(Bahr et al., 2003). Established glioma cell lines and primary cultures
were maintained in Dulbecco’s modified eagle medium (DMEM) con-
taining 10% foetal calf serum (FCS) (Biochrom KG, Berlin, Germany),
100 IU/ml penicillin and 100 mg/ml streptomycin (Life Technologies,
Karlsruhe, Germany). pSUPER puro transfected cells were maintained
in medium containing 2 mg/ml puromycin (Sigma, Deisenhofen,
Germany). Lomustine [CCNU, 1-(2-chloroethyl)-3-cyclohexyl-1-
nitrosourea] and vincristine as well as all other chemicals not specified
below were purchased from Sigma.
Immunoblot analysis
Immediately after incubation, cells were washed with ice-cold PBS
and harvested into ice-cold PBS containing protease inhibitors.
Cellular lysates were prepared as described (Steinbach et al., 2003)
and subjected to SDS–PAGE analysis. Membranes were probed with
antibodies to phospho-p90RSK (P-p90RSK) (Ser380), phospho-Akt
(P-Akt) (Ser473), phospho-p42/44 mitogen-activated protein kinase
(P-p42/44 MAPK) (Thr202/Tyr204), phospho-RPS6 (P-RPS6)
(Ser235/236) and eIF4E (employed here as internal standard for
equal protein loading) utilizing the Pathscan Multiplex Western
Cocktail I or with antibodies to P-Akt (Ser473), Akt, P-p42/44
MAPK (Thr202/Tyr204), phospho-S6K1 (P-S6K1) (Thr389), S6K1,
phospho-4E-BP1 (P-4E-BP1) (Thr37/46), 4E-BP1 and mTOR all
purchased from Cell Signaling (Beverly, MA, USA). The antibody to
hypoxia inducible factor (HIF)-1 a was purchased from R&D Systems
(Minneapolis, MN, USA) and the antibody to cyclin D1 and p42/44
MAPK was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The secondary anti-rabbit and anti-goat antibodies were purchased
from Santa Cruz Biotechnology. Enhanced chemiluminescence (ECL+)
(Amersham, Little Chalfont, UK) was used for detection.
Cell growth and viability assays
Cell growth was assessed by crystal violet staining as previously
described (Roth et al., 1997). Further cultures derived from
primary glioblastoma surgery specimens were pulsed with
[methyl-3H]thymidine (1 mCi; Amersham) on day 2 and collected
16 h later using a cell harvester (Tomtec, Hamden, CT). Incorporated
radioactivity was bound to a glass fibre filtermat (Wallac, Turku,
Finland). The filtermat was wetted with Ultima Gold Scintillation
Cocktail (Packard, Dreieich, Germany) and radioactivity was deter-
mined in a Wallac 1450 Microbeta Plus Liquid Scintillation Counter.
For cell viability analysis, the cells were washed with ice-cold PBS,
stained with 5 mg/ml propidium iodide (PI) in PBS and analysed by
flow cytometry employing a DAKO CyAn flow cytometer and
Summit 4.2. software. Alternatively, cell viability was analysed by
lactate dehydrogenase (LDH) release assays (Steinbach et al., 2004).
CD95L was obtained from the supernatant of CD95L-transfected
N2A murine neuroblastoma cells (Roth et al., 1997). For the detection
of chemotherapy-induced cell death, the cells were plated on 96 well
plates (Falcon, Becton-Dickinson) at 1.5104/well and allowed
to attach overnight. Then the cells were incubated with or without
rapamycin and chemotherapeutics for 72 h in serum-free medium and
stained with crystal violet.
Induction of hypoxia
Hypoxia was induced by incubating cells in Gas Pak pouches for
anaerobic culture (Becton Dickinson, Heidelberg, Germany)
(Steinbach et al., 2003). Briefly, the cells were plated on 96 well
plates at 2104/well or petri dishes of various sizes and allowed to
attach overnight. Then the cells were incubated in serum-free DMEM
without glucose (Gibco BRL, Basel, Switzerland) adjusted to 2 mM
glucose under normoxia or hypoxia for the indicated time periods.
Equal cell densities were ensured by crystal violet staining when
comparing vehicle and rapamycin preincubated cells as wells as
LNT-229 puro and LNT-229 mTOR-directed small hairpin sequence
(mTORsh) cells.
Generation of LNT-229 mTORsh
knockdown cells
The pSUPER plasmid was obtained from R. Agami (Amsterdam,
The Netherlands). A puromycin cassette was inserted into the NaeI
site. The mTOR-specific oligonucleotide sequences GATCCCC
ACTTCGAAGCTGTGCTACA ttcaagaga TGTAGCACAGCTTCGAAGT
TTTTTGGAAA and TCGATTTCCAAAAA ACTTCGAAGCTGTGCTACA
tctcttgaa TGTAGCACAGCTTCGAAGT GGG [nucleotides (nt) 5 469-
5 487] were obtained from Biomers.net (Ulm, Germany) and cloned
into the BglII and SalI sites of pSUPER. The mTOR-specific parts of
the sequences are underlined. For the generation of stable mTORsh
transfectants, pSUPER puro control or mTORsh plasmids were
introduced using FuGene6 transfection reagent (Roche).
ATP assay
Immediately after normoxic or hypoxic incubation, the plates were
placed on ice and the cells were pelleted by centrifugation and lysed
in ATP releasing reagent (Sigma). The ATP concentration was deter-
mined by luciferase assay with the CLS II kit (Boehringer, Mannheim,
Germany) (Steinbach et al., 2003).
JC-1 assay
Following treatment as indicated, the cells were washed in PBS and
incubated for 15 min in JC-1 staining reagent (Biocarta, Hamburg,
Germany) at 37C. Then the cells were washed once in assay
buffer, resuspended in PBS and analysed by flow cytometry.
Glucose assay
Immediately after hypoxia the cells were pelleted by centrifugation
and the supernatant was assayed for glucose employing the Gluco-
quant kit (Roche).
Statistical analysis
Quantitative data obtained for cell density by crystal violet, LDH-
release, glucose and ATP concentrations are expressed as mean and
SD as indicated. P-values for cell density by crystal violet, LDH-release,
glucose and ATP concentration were derived from two-tailed student’s
t-tests. Values of P40.05 were considered not significant (NS), values
of P50.05 and P50.01 were considered significant and highly
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significant (Excel, Microsoft, Seattle, WA, USA). When multiple tests
were performed significance levels (a values) were adjusted using the
Holm-Bonferroni method.
Results
Preferential inhibition of the p70
isoform of S6K1 by rapamycin in
human malignant glioma cells
To establish the specific pattern of rapamycin action in human
malignant glioma cells, PTEN wildtype LNT-229 or PTEN mutant
U87MG cells were exposed to rapamycin. Phosphorylation of the
70 kD isoform of the direct mTOR target S6K1, which correlates
with its activity (Harris and Lawrence, 2003), was inhibited by
rapamycin in a concentration-dependent fashion and abolished
at a concentration of 100 nM in both cell lines (Fig. 1).
Therefore, this concentration, which also corresponds to the effec-
tive rapamycin concentrations required in other malignant glioma
and non-glioma cell lines (Peng et al., 2002; Tanaka et al., 2007;
Wei et al., 2008), was used as a standard for subsequent experi-
ments. Of note, the 85 kD isoform of S6K1 which is located in the
nucleus and known to be less abundant than the 70 kD isoform in
some cell lines (Reinhard et al., 1994), was much less sensitive to
inhibition by rapamycin, particularly in U87MG cells.
CD95 ligand- and chemotherapy-
induced cell death: dissociation of the
effects of EGFR inhibition and mTOR
inhibition
EGFR-dependent signalling is a major determinant of susceptibility
towards death ligand/CD95L- and chemotherapy-induced cell
death in human malignant glioma cells. It has been suggested
that the proapoptotic properties of EGFR inhibitors are mediated
by decreased mTOR signalling. To compare the effects of mTOR
inhibition with those of inhibition of EGFR, PI3K or MEK, LNT-229
and U87MG cells were exposed to rapamycin, PD153035,
LY294002 and U0126 alone or in combination. The specificity
of pathway inhibition was assessed by immunoblot analysis for
phosphorylated p90RSK, Akt, p42/44 MAPK, RPS6, 4E-BP1 and
total eIF4E or 4E-BP1 as a loading control (Fig. 2A). In PTEN
wildtype LNT-229 cells, only the EGFR inhibitor PD153035
abolished RPS6 phosphorylation when administered alone
(Fig. 2A). In contrast, rapamycin, LY294002 and U0126 only
partially inhibited the phosphorylation of RPS6. Co-inhibition of
PI3K and MEK with LY294002 and U0126 mimicked the effects
of PD153035 on P-RPS6, suggesting that both branches of EGFR
signalling, PI3K and MEK, must be inhibited for abrogation of
ribosomal protein S6 phosphorylation. Accordingly, ribosomal pro-
tein S6 phosphorylation was still detectable, albeit at a much lower
level, in S6K knockout cells (Pende et al., 2004) and ribosomal
protein S6 can also be phosphorylated by p90RSK (Roux et al.,
2007). Thus, dual mechanisms originating from MEK as well
as from mTOR regulate the indirect mTOR target ribosomal
protein S6. In U87MG cells, rapamycin was the most effective
agent for ribosomal protein S6 inhibition, whereas PD153035
and U0126 had no effect (Fig. 2A). The inefficient inhibition of
ribosomal protein S6 phosphorylation by PD153035 is plausible
given that U87MG cells lack functional PTEN (Ishii et al., 1999).
No agent alone abrogated Thr37/46 4E-BP1 phosphorylation with
roughly equivalent effects of rapamycin, PD153035 and
LY294002 in LNT-229 and of rapamycin and LY294002 in
U87MG cells. The most pronounced effects on 4E-BP1 phosphory-
lation were achieved by combining rapamycin with PD153035 or
LY294002 and the effect of these inhibitors was most pronounced
in the slowest migrating g band of 4E-BP1.
The cell death-promoting potential of mTOR inhibition was then
assessed by exposing LNT-229 or U87MG cells to CD95 ligand in
the presence of rapamycin, PD153035, LY294002 or U0126 alone
or combined as indicated (Fig. 2A, lower panel). Rapamycin alone
sensitized neither LNT-229 nor U87MG cells to CD95 ligand.
Rapamycin also failed to induce synergistic or additive cytotoxic
effects when combined with PD153035, LY294002 or U0126
(Fig. 2A, lower panel). In LNT-229 cells PD153035 was the only
agent which substantially sensitized to CD95 ligand. While both
substances alone did not modulate CD95 ligand-induced cell
death, the combination of LY294002 and U0126 also sensitized
the cells, although to a lesser degree than PD153035. Notably,
the combination of rapamycin with U0126 which abolished
ribosomal protein S6 phosphorylation in the immunoblot analysis
was inefficient. Largely, similar results were obtained in U87MG
cells (Fig. 2A, lower panel) with PD153035 as the most potent
sensitizing agent and rapamycin failing to show any effect alone or
in any of the investigated combinations. Although after correction
for multiple testing only PD153035, PD153035 plus rapamycin
and LY294002 plus U0126 achieved significance in U87MG
cells. In parallel experiments with LNT-229 and U87MG cells,
CD95 ligand-induced cell death in the presence of rapamycin
or PD513035 was analysed by LDH release with similar results,
indicating that the CD95 ligand-mediated effect is not due to an
inhibition of proliferation rather than cell death (data not shown).
Since mTOR exerts its effect partially through modulation of
mRNA translation, we asked whether pretreatment of glioma
cells with rapamycin, to allow for the time necessary to reach
the new levels of target proteins, alters susceptibility to CD95
Figure 1 Concentration-dependent inhibition of S6K1
phosphorylation by rapamycin in human malignant glioma
cells. LNT-229 or U87MG cells were exposed to vehicle or
rapamycin (0.1–1000 nM) in serum-free medium for 20 min.
Levels of phosphorylated and total S6K1 protein were analysed
by immunoblot.
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ligand-mediated apoptosis. Again, rapamycin was ineffective (data
not shown). Notably, exposure to rapamycin up to 24 h did not
induce growth inhibition or cell death in any of these experiments
as assessed by crystal violet staining or LDH release assays.
Concerning inhibitor specificity, we have previously shown that
the EGFR inhibitor AG1478 has similar effects as PD153035 both
with regard to sensitivity to apoptosis (Steinbach et al., 2002) and
protection from hypoxia-induced cell death (Steinbach et al.,
2004). To delineate consequences for clinical practise, we
performed additional experiments with the clinically used EGFR
inhibitor erlotinib (Supplementary Fig. S1A). We also performed
experiments with lower inhibitor concentrations of the PI3K and
MEK inhibitors (5 mM LY294002 and 10 mM U0126) since their
necessary concentrations remain controversial, with similar results
(compare Fig. 2A and Supplementary Fig. S1C).
To further clarify the level of EGFR-dependent signal transduc-
tion that mediates the proapoptotic consequences, we performed
experiments with the Akt-specific inhibitor Akt inhibitor VIII
which blocks Akt phosphorylation and activation by an allosteric
mechanism (DeFeo-Jones et al., 2005). Phosphorylation of Akt
was abolished with 1mM Akt inhibitor VIII (Supplementary
Fig. S2A). Akt inhibitor VIII sensitized LNT-229 cells towards
CD95 ligand- as well as towards TRAIL-mediated apoptosis
(Supplementary Fig. S2B and C).
Figure 2 Effects of pharmacological manipulation of EGFR-Akt-mTOR signalling on CD95 ligand- and chemotherapy-induced cell
death. (A) Upper panel: LNT-229 or U87MG cells were exposed to vehicle, rapamycin (100 nM), PD153035 (10 mM), LY294002
(10 mM) or U0126 (20 mM) alone or combined as indicated in serum-free medium for 20 min for immunoblot analysis. Cellular lysates
were analysed for P-p90RSK, P-Akt, P-p42/44 MAPK, P-RPS6, eIF4E, P-4E-BP1 or 4E-BP1. Lower panel: LNT-229 cells were exposed to
100 U/ml CD95L, U87MG cells were exposed to 20 U/ml CD95L for 24 h. Cell density was assessed by crystal violet staining, cell
densities are normalized and shown as percentages of the cell densities when inhibitors were used as single agents or combinations
without CD95L (n= 3, *P50.05 corrected for multiple testing, student’s t-test). (B) LNT-229 cells were co-incubated with vehicle or
100 nM rapamycin and exposed to CCNU or vincristine for 72 h. Cell density was assessed by crystal violet staining (n= 3, all P-values
were40.05, student’s t-test).
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Rapamycin is currently investigated in combination with several
chemotherapeutics, including vincristine, VP-16, cisplatin and
others for various malignancies (Haritunians et al., 2007). To
test whether rapamycin might enhance the cytotoxicity of
chemotherapeutic drugs administered for the treatment of patients
with malignant glioma, we co-incubated LNT-229 cells with
rapamycin and CCNU or vincristine (Fig. 2B). The cytotoxic effects
of these drugs were not altered by co-incubation with rapamycin.
It has recently been reported that rapamycin can cause activation
of Akt and p42/44 MAPK through relieving feedback inhibitory
mechanisms. To further address this issue, we performed
immunoblot experiments with LNT-229 and U87MG cells after
up to 24 h of exposure to rapamycin. However, rapamycin did
not enhance Akt phosphorylation (Ser473) at any timepoint
(Supplementary Fig. S3A and B and Fig. 4A, lanes 2, 3). Stably
transfected mTORsh cells also have unaltered P-Akt levels
(Fig. 5D, lanes 1–4). Therefore, the feedback inhibition of Akt
that has been found in the PTEN wild type prostate cancer
cell line DU-145 and the breast cancer cell line MCF-7
(O’Reilly et al., 2006) is not present in LNT-229 or U87MG
glioblastoma cells. We also failed to detect an increase in
p42/44 MAPK phosphorylation in cells exposed to rapamycin
(Supplementary Fig. S3A and B and Fig. 4A, lanes 2, 3) and
mTORsh cells (Fig. 5D, lanes 1–4) in contrast to the findings
reported in other tumour types exposed to mTOR inhibitors
(Carracedo et al., 2008).
Rapamycin causes growth inhibition in
human malignant glioma cells but is
not cytotoxic
Rapamycin exerts antiproliferative effects in a variety of human
tumour cell lines (Easton and Houghton, 2006). Cytotoxic effects
have also been reported in the human malignant glioma cell lines
U87MG, T98G and U373MG (Takeuchi et al., 2005). To differ-
entiate growth inhibitory from cytotoxic effects of rapamycin, cell
growth and viability were assessed in parallel by crystal violet
staining and flow cytometry for PI uptake in cells exposed to
rapamycin or vehicle. In growth curves established in the presence
of rapamycin, cell growth was decreased both in serum-free
medium and medium containing 10% FCS in the cell lines
LNT-229 and U87MG (Fig. 3A and B, left panel). In the SV40-
transformed astrocytic cell line SV-FHAS, the growth-inhibitory
effect of rapamycin was also potent with a cell growth of
550% in relation to the vehicle control in medium containing
10% FCS (data not shown). Cell viability was unaffected by
exposure to rapamycin for up to 72 h (Fig. 3A and B, right
panel). Similar results were obtained in PTEN mutant T98G
human malignant glioma cells and in long-term cultures with
regular administration of rapamycin for several weeks (data not
shown). PTEN wildtype LNT-229 and PTEN mutant U87MG and
T98G cells showed similar sensitivity to rapamycin-induced growth
inhibition without detection of rapamycin cytotoxicity. Also, similar
growth-inhibitory effects of rapamycin in the absence of cytotoxi-
city were observed in all primary cultures of human malignant
gliomas investigated (Fig. 3C, Supplementary Fig. S4A). Since
the concomitant PI-staining did not reveal changes in the
number of dead cells, the observed effects are likely due to
changes in proliferation. This is also corroborated by reduced
[methyl-3H]thymidine incorporation in four investigated primary
glioblastoma cultures (Supplementary Fig. S4B).
Figure 3 Effects of rapamycin on viability and proliferation.
(A–C), to assess proliferation, LNT-229 (A), or U87MG (B) cells
and primary glioblastoma cultures (C) were exposed to vehicle
or 100 nM rapamycin in serum-free medium or medium
containing 10% FCS. Cell density was assessed by crystal violet
staining (n5 3, *P50.05, **P50.01, Student’s t-test). The
cell growth of vehicle-treated cells after 72 h corresponds to
100%. For viability analysis, cells were incubated in serum-free
medium with rapamycin for 72 h. PI uptake was quantified
by flow cytometry. The spontaneously occurring percentage
of PI-positive cells was not enhanced by rapamycin.
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Hypoxia inhibits mTOR signalling and
inhibition of mTOR signalling by
rapamycin protects human malignant
glioma cells from hypoxia-induced
cell death
Hypoxia suppresses mTOR activity via the proteins REDD and
TSC1/TSC2 (Brugarolas et al., 2004). This mechanism is consid-
ered an adaptive response allowing cells to survive under hypoxic
and nutrient-deprived conditions by decreasing mTOR-dependent
metabolic demands. To explore hypoxia-induced alterations of
mTOR signalling, we employed a paradigm of hypoxia with partial
glucose depletion and a defined mechanism of energy-dependent
cell death with mainly necrotic features (Steinbach et al., 2003,
2004). The activity with mTOR targets was analysed by phospho-
specific immunoblots. Under normoxic conditions, glucose
restriction and serum withdrawal decreased the phosphorylation of
Akt, RPS6 and S6K1 and shifted the pattern of the 4E-BP1 isoforms
towards the lower hypophosphorylated a and b bands in LNT-229
cells (Fig. 4A). Rapamycin further suppressed S6K1 phosphorylation.
Hypoxia had dramatic effects on mTOR signalling, abolish-
ing phosphorylation of RPS6 and S6K1 and shifting 4E-BP1
phosphorylation utmost towards the lowest a band. Hypoxia
also decreased the phosphorylation of p42/44 MAPK and this
effect was enhanced by PD153035 (Fig. 4A). We had previously
hypothesized that the protection from hypoxia conferred by inhi-
bition of EGFR signalling is mediated by decreased mTOR activity
(Steinbach et al., 2004). We therefore exposed LNT-229 cells to
hypoxia in the presence of rapamycin or PD153035. Hypoxia-
induced cell death was indeed reduced by rapamycin (Fig. 4B).
However, rapamycin was less potent than PD153035, indicating
that PD153035 might exert its hypoxia-protective functions only
partially via mTOR. Note that while PD153035 was cytotoxic
under normoxic conditions, rapamycin was not (Fig. 4B, left
graph). The hypoxia-protective effect of rapamycin became appar-
ent at concentrations as low as 1 nM, with largely similar effects of
concentration of 10–1000 nM in LNT-229 cells (Supplementary
Fig. S5A). Thus, low concentrations of rapamycin that are
achieved in glioblastoma in vivo (Cloughesy et al., 2008)
have the potential to protect glioblastoma cells from hypoxia
while 1000-fold higher concentrations fail to induce cell death.
The autophagy inhibitor 3-methyl-adenine did not abrogate
PD153035 or rapamycin-mediated protection from hypoxia-
induced cell death (data not shown). Also in ultrastructural
analyses autophagy was not detectable in our model of hypoxia-
induced cell death (Steinbach et al., 2005). Notably, rapamycin
also protected cells derived from two out of three tested primary
Figure 4 Effects of rapamycin on hypoxia-induced cell death and hypoxia-induced alterations of mTOR signalling. (A) LNT-229 cells
were cultured in medium containing 10% FCS or in serum-free medium containing 2 mM glucose and exposed to vehicle, 100 nM
rapamycin or 10 mM PD153035 under normoxia or hypoxia for 8 h as indicated. Cellular lysates were analysed with antibodies to
P-p90RSK, P-Akt, P-p42/44 MAPK, P-RPS6, eIF4E, P-S6K1, S6K1, P-4E-BP1, 4E-BP1 or actin. (B) LNT-229 cells were incubated in
serum-free medium containing 2 mM glucose and exposed to vehicle, 100 nM rapamycin or 10 mM PD153035 under normoxia
or hypoxia for 20 h. Cytotoxicity was assessed by lactate dehydrogenase release (n= 4, NS P40.05, **P50.01, student’s t-test).
(C) LNT-229 cells were preincubated for 24 h in serum-free medium with either vehicle or 100 nM rapamycin, followed by exposure
to normoxia or hypoxia in serum-free medium containing 2 mM glucose in the presence of rapamycin or vehicle for 20 h.
Hypoxia-induced cell death was assessed by lactate dehydrogenase release (n= 4, **P50.01, student’s t-test). Note that the
slightly higher amount of hypoxia-induced cell death in untreated cells compared with B is due to a higher cell growth.
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Figure 5 Small hairpin RNA-mediated gene silencing of mTOR: effects on chemotherapy-induced cell death, proliferation and hypoxia-
induced cell death. (A) LNT-299 cells were transfected with either the empty pSUPER puro vector (puro) or the pSUPER puro plasmid
with the mTORsh. Cellular lysates were analysed by immunoblot with antibodies to mTOR and actin. (B) LNT-229 puro or mTORsh
cells were incubated in serum-free medium for 24 h and subsequently exposed to serum-free medium containing 100 ng/ml EGF and
50 ng/ml IGF-1 for 10 min. Cellular lysates were analysed by immunoblot with antibodies to P-4E-BP1, 4E-BP1 or actin. (C) LNT-229
puro or mTORsh cells were incubated in serum-free medium for 23 h then rapamycin was added to a final concentration of 100 nM.
After 1 h cells were exposed to serum-free medium containing 100 ng/ml EGF and 50 ng/ml IGF-1 and 100 nM rapamycin for 20 min.
Cellular lysates were analysed by immunoblot with antibodies to P-4E-BP1 or actin. (D) LNT-229 puro and mTORsh cells were
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glioblastoma cultures from hypoxia-induced cell death, whereas
PD153035 was effective in all (Supplementary Fig. S5B).
Furthermore, inhibition of Akt conferred protection from hypoxia
(Supplementary Fig. S2D); erlotinib also protected LNT-229 cells
from hypoxia (Supplementary Fig. S1B). Since mTOR exerts its
effects in part via alterations of translation, the full impact of
inhibition of mTOR may only become apparent when the
levels of the target proteins have reached their (new) equili-
brium. We therefore preincubated LNT-229 cells with rapamycin
prior to exposure to hypoxia. Equal cell density in the differently
preincubated cells was ensured by crystal violet staining prior to
hypoxic conditioning and glucose restriction. Preincubation con-
siderably enhanced the hypoxia-protective effect of rapamycin
(Fig. 4C).
Small hairpin RNA-mediated gene
silencing of mTOR confers protection
from hypoxia-induced cell death
Rapamycin exclusively inhibits the mTOR complex 1 (mTORC1),
while the mTOR complex 2 (mTORC2), which contains mTOR
in combination with different adaptor proteins, is resistant to
rapamycin. To fully explore the role of the mTOR protein, we
investigated the role of inhibition of mTOR using small hairpin
RNA-mediated gene-silencing in stably transfected cells employing
the pSUPER plasmid (Brummelkamp et al., 2002). The experi-
ments were conducted with early-passage pooled clones.
mTOR protein levels in LNT-229 cells stably transfected with the
mTOR-directed sequence (LNT-229 mTORsh) were 20% of
those in LNT-229 cells transfected with the empty control vector
(LNT-229 puro) (Fig. 5A). To investigate how gene suppression of
mTOR impairs mTOR-mediated signal transduction, we stimulated
serum-starved LNT-229 puro or mTORsh cells with EGF and IGF-1
to test for stimulated eukaryotic initiation factor 4E binding protein
1 (4E-BP1) hyperphosphorylation (Brunn et al., 1997). After 24 h
of incubation in serum-free medium, 4E-BP1 was detectable in
both puro and mTORsh cells in the a and b bands evidencing a
low-phosphorylation state (Fig. 5B). In puro cells equal amounts of
protein in the a and b bands were detectable, in mTORsh cells the
extent of hypophosphorylation was more pronounced with more
4E-BP1 in the a than in the b band. Ten minutes incubation with
EGF/IGF-1 led to an increase in phosphorylation of 4E-BP1 and a
resulting band shift in both puro and mTORsh cells. Puro cells
exhibited almost equal distributions of a, b and g bands, whereas
a and b bands were still dominating in mTORsh cells indicating
a lesser degree of 4E-BP1 phosphorylation. Similar results were
obtained with an antibody that detects total 4E-BP1. Thus,
phosphorylation of the mTOR target 4E-BP1 is suppressed in
mTORsh cells, confirming the functionality of the gene suppres-
sion. Rapamycin addition to the serum-starved cells 1 h prior to
stimulation with EGF and IGF-1 abolished 4E-BP1 hyperphosphor-
ylation as evidenced by the lacking g band in cells incubated with
EGF/IGF-1 (Fig. 5C). To test whether mTOR gene suppression has
effects on EGFR-dependent signalling in our hypoxia model, we
compared the phosphorylation patterns of p90RSK, p42/44
MAPK, Akt and RPS6 using total eIF4E as a loading control
(Fig. 5D). In contrast to LNT-229 puro cells, RPS6 phosphorylation
was already abolished in mTORsh cells after 8 h incubation in
serum-free medium containing 2 mM glucose under normoxia
(Fig. 5D, lanes 3, 4), again indicating an impaired mTOR activity
in mTORsh cells. In contrast, equal amounts of P-RPS6 were
detectable in cells incubated in medium containing 10% FCS
(Fig. 5D, lanes 1, 2).
Thus, with supra-physiological stimulation of starvation-sensitive
pathways, the residual mTOR activity in the mTORsh cells is
sufficient to maintain ribosomal protein S6 phosphorylation. The
phosphorylation patterns of the other investigated proteins not
downstream of mTOR were comparable to those observed in
LNT-229 wildtype cells (Fig. 4A). Of note, after 24 h incubation
in serum-free medium without glucose deprivation LNT-229
mTORsh cells also exhibited a weaker ribosomal protein S6 phos-
phorylation than puro control cells (data not shown). To test
whether gene suppression of mTOR modulates the sensitivity to
the chemotherapeutics CCNU or vincristine, we exposed LNT-229
puro or mTORsh cells to these drugs (Fig. 5E). Stable mTOR-
knockdown cells were less sensitive to chemotherapy-induced
cell death than puro control cells and rapamycin-treated cells.
This effect may be explained either by long-term alterations of
protein expression in the mTORsh cells or by a mTORC2-mediated
mechanism.
To characterize the effect of gene suppression of mTOR on
proliferation, growth curves in serum-free medium and medium
containing 10% FCS were established in LNT-229 mTORsh and
puro cells in the absence or presence of rapamycin. Gene suppres-
sion of mTOR reduced proliferation to a similar degree as
rapamycin (Fig. 5F). Rapamycin further decreased the proliferation
of LNT-229 mTORsh cells. Similar effects were observed with
medium containing 10% FCS (Fig. 5F, lower panel). The additive
growth-inhibitory effect may be due to inhibition of the residual
mTOR protein in the mTORsh cells. Alternatively, suppression of
the mTORC2 function in the LNT-229 mTORsh cells may add
to the effect of rapamycin.
incubated in medium containing 10% FCS or in serum-free medium containing 2 mM glucose under normoxia (N8) or hypoxia (H8) for
8 h as indicated. Cellular lysates were analysed with antibodies to P-p90RSK, P-Akt, P-p42/44 MAPK, P-RPS6 and eIF4E. (E) LNT-229
puro and mTORsh cells were exposed to CCNU or vincristine in serum-free medium for 72 h. Cell density was assessed by crystal violet
staining (n= 3, *P50.05, **P50.01, student’s t-test). (F) LNT-229 puro and mTORsh cells were incubated in serum-free medium or
medium containing 10% FCS and exposed to vehicle or 100 nM rapamycin for the indicated periods of time. Cell density was assessed
by crystal violet staining (n= 3, NS P40.05, *P50.05, **P50.01, student’s t-test). (G) LNT-229 puro and mTORsh cells were
incubated in serum-free medium containing 2 mM glucose and exposed to vehicle, 100 nM rapamycin or 10 mM PD153035 in hypoxia
for 20 h. Cytotoxicity was assessed by lactate dehydrogenase release (n= 4, *P50.05, **P50.01, student’s t-test).
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We then compared the sensitivity to hypoxia of LNT-229
mTORsh and puro cells. LNT-229 mTORsh cells were resistant
to hypoxia-induced cell death (Fig. 5G). The protection conferred
by inhibition of EGFR signalling with PD153035 was more pro-
nounced than that of gene suppression of mTOR. In addition,
PD153035, in contrast to rapamycin, enhanced the protection
from hypoxia observed in mTORsh cells. Therefore, mTOR-
independent signalling cascades downstream of the EGFR appear
to contribute to the protective effect of PD153035. Protection
from hypoxia-induced cell death in LNT-229 mTORsh in compar-
ison to LNT-229 puro cells was also detectable at the level of flow
cytometric assessment of PI staining (data not shown).
Antagonism of mTOR signalling
preserves cellular ATP and
mitochondrial integrity
We have previously demonstrated that EGFR inhibition reduces
glucose consumption, delays ATP depletion and preserves
mitochondrial integrity during hypoxia (Steinbach et al., 2004).
Similarly, in LNT-229 mTORsh cells as well as in rapamycin-
pretreated LNT-229 cells, the hypoxia-induced depletion of ATP
was delayed (Fig. 6A and B). Further, the percentage of cells with
intact mitochondrial membrane potential after 16 h of hypoxic
incubation was higher in LNT-229 mTORsh than in LNT-229
Figure 6 Effects of rapamycin and mTOR gene suppression on energy homeostasis. (A) LNT-229 puro or mTORsh cells were
incubated in serum-free medium containing 2 mM glucose and exposed to vehicle or 10 mM PD153035 under normoxia or hypoxia for
12 h. Cellular ATP (per cent of normoxic controls) was determined by luciferase assay (n= 4, **P50.01, student’s t-test). (B) LNT-229
cells were preincubated in serum-free medium with vehicle or 100 nM rapamycin for 24 h. Subsequently, the cells were incubated in
serum-free medium containing 2 mM glucose and exposed to vehicle or 100 nM rapamycin under normoxia or hypoxia for 12 h.
Cellular ATP was determined by luciferase assay (n= 3, *P50.05, student’s t-test). (C) LNT-229 puro and mTORsh cells were
incubated in serum-free medium containing 2 mM glucose under normoxia or hypoxia for 16 h. Mitochondrial membrane potential was
determined by JC-1 staining and analysed by flow cytometry. (D) LNT-229 puro or mTORsh cells were incubated in serum-free
medium containing 2 mM glucose under hypoxia for 4 h. Glucose concentration in the supernatant was determined enzymatically
(n= 4, NS P40.05, student’s t-test). (E) LNT-229 cells were incubated in medium containing 10% FCS or in serum-free medium
containing 2 mM glucose and exposed to vehicle, 100 nM rapamycin or 10 mM PD153035 under normoxia or hypoxia for 8 h. Cellular
lysates were analysed by immunoblot with antibodies to HIF-1 a or actin. (F) LNT-229 puro or mTORsh cells were incubated in serum-
free medium containing 2 mM glucose under normoxia or hypoxia for 8 h. Cellular lysates were analysed by immunoblot with
antibodies to HIF-1 a or actin. (G) LNT-229 cells were incubated in medium containing 10% FCS or serum-free medium and exposed
to vehicle or 100 nM rapamycin for 24 h. Cellular lysates were analysed by immunoblot with antibodies to cyclin D1 or actin.
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puro cells (Fig. 6C). Rapamycin preincubation, unlike EGFR inhibi-
tion, did not alter glucose consumption under hypoxic conditions
(data not shown) in accordance with a previous report that
rapamycin does not alter glucose consumption in LN-229 cells
under normoxia (Wei et al., 2008). Glucose consumption was
also unchanged in LNT-229 mTORsh cells compared with LNT-
229 puro cells (Fig. 6D). These results indicate that antagonizing
mTOR reduces energy demand, thus preserving cellular viability
independent from glucose consumption.
HIF-1 a is considered one mediator of mTOR-induced adaptive
responses to hypoxia and HIF-1 a protein levels have been
reported to decrease in response to mTOR inhibition with the
rapamycin analogue CCI-779 in kidney cancer cells (Thomas
et al., 2006). Independent from its effects in angiogenesis,
HIF-1 a adapts metabolic processes by altering the transcription
of a large number of target genes (Semenza et al., 1994).
Therefore we investigated HIF-1 a protein by immunoblot analysis
in LNT-229 cells exposed to rapamycin or PD153035, both under
normoxic and hypoxic conditions (Fig. 6E). Neither rapamycin nor
PD153035 altered the induction of HIF-1 a by hypoxia. HIF-1 a
levels were also maintained in hypoxic LNT-229 mTORsh cells
(Fig. 6F).
Cycling cells are more sensitive to induction of apoptosis and
have higher energy consumption. We therefore investigated the
expression of the cell cycle regulator cyclin D1, another protein
which that has been reported to be regulated in a mTOR-
dependent fashion (Averous et al., 2008). Rapamycin did not
alter cyclin D1 protein levels (Fig. 6G). Thus, malignant glioma
cells maintain the expression of molecules critical for proliferation,
angiogenesis and metabolic adaptive function independently
from mTOR.
Discussion
In an attempt to dissociate pathways responsible for two opposing
major effects of EGFR signalling, we have explored to what extent
mTOR mediates proapoptotic effects and metabolic hypoxia-
protective effects of EGFR inhibition.
We find that rapamycin is not cytotoxic to human malignant
glioma cells as assessed by LDH release or PI assays. Of note,
neither the viability of permanent cell lines nor that of primary
cultures derived from glioma surgical specimens was affected by
rapamycin (Fig. 3A–C, Supplementary Fig. S4A). Further, whereas
EGFR or Akt inhibition sensitized malignant glioma cells to the
death ligand CD95 ligand or TRAIL, rapamycin failed to sensitize
these cells to CD95 ligand, TRAIL or chemotherapeutic drugs such
as CCNU or vincristine (Fig. 2A and B, Supplementary Figs S1A,
S2B and C). Notably, the failure of rapamycin was not due to
feedback activation of Akt or p42/44 MAPK which has been
described in other tumour types (O’Reilly et al., 2006;
Carracedo et al., 2008) (Supplementary Fig. S3A and B).
Therefore, dissociation of proapoptotic effects at the level of Akt
remains the most plausible explanation for the absence of
cytotoxicity of mTOR antagonistic strategies.
These findings are corroborated by similar results observed
in response to mTOR gene suppression (Fig. 5E and F).
Stable mTOR-knockdown cells were even less sensitive to
chemotherapy-induced cell death than puro control cells. This
observation is in accordance with a recent report from Lee et al.
(2007) who report that antagonism of mTOR in TSC-deficient
fibroblasts protects these cells against DNA-damage and etoposide
by reducing p53-dependent cell death.
Importantly, mTOR inhibition also did not induce synergistic
effects when combined with inhibitors of EGFR, PI3K or MAPK,
respectively (Fig. 2A). Since pilot trials investigating combinations
of inhibitors of EGFR and mTOR are underway (Doherty et al.,
2006; Reardon et al., 2006), this is of particular concern.
The widely held assumption that downstream effects of PI3K
and Akt are necessarily mediated by mTOR is also challenged by
the findings of Opel et al., who found that Akt activation is
associated with decreased event-free or overall survival in neuro-
blastoma patients whereas phosphorylation of the prototypical
mTOR target ribosomal protein S6 is not (Opel et al., 2007).
The same authors have recently reported that inhibition of
mTOR fails to sensitize both PTEN wildtype and PTEN mutant
human malignant glioma cells from established cell lines as well
as from primary cultured glioblastoma samples towards cell death
induced by TRAIL or chemotherapy, in line with our findings (Opel
et al., 2008). Thus, at least for glioma cells, the current view of
mTOR as an apoptosis-modulating target of Akt needs to be
reconsidered.
It is intriguing to speculate that the observed dissociation of
hypoxia-protective effects and antiapoptotic effects on the level
of mTOR could be due to effects of EGFR inhibition that are not
mediated by impaired EGFR kinase function as recently described
(Weihua et al., 2008). However, it is notable that the effects
described by Weihua et al. were only observed with gene suppres-
sion, which reduces EGFR protein expression necessary for the
function of the glucose transporter SGLT1, not with EGFR kinase
inhibitors such as PD153035, which was employed in our study.
The similar effects achieved with erlotinib support this conclusion
(Supplementary Fig. S1A and B).
Further, both types of consequences of EGFR inhibition—
protection from hypoxia, as well as enhanced apoptosis—can be
mimicked by inhibitors of EGFR-dependent signal transduction.
Co-inhibition of PI3K and MEK, in contrast to co-inhibition of
mTOR and MEK, sensitizes glioma cells towards CD95 ligand
(see Fig. 2A and Supplementary Fig. S1C). Protection from
hypoxia-induced cell death in cells co-exposed to LY294002 and
U0126 has previously been demonstrated (Steinbach et al., 2004).
The experiments with the Akt-specific inhibitor Akt inhibitor VIII
further clarify the level of EGFR-dependent signal transduction
that mediates the proapoptotic consequences (Supplementary
Fig. S2B and C) (DeFeo-Jones et al., 2005). Since inhibition of
Akt also conferred protection from hypoxia (Supplementary
Fig. S2D), our data are well compatible with a dissociation of
pro-apoptotic and hypoxia-protective effects downstream of Akt.
A recent report implicates protein kinase C (PKC) as the mediator
of EGFR signalling to mTOR independently of Akt, dissecting
mTOR from the Akt-signalling cascade and challenging the
widely held assumption of mTOR as a downstream target
of Akt (Fan et al., 2009). In our experimental setting,
however, Akt inhibition mimicked both the pro-apoptotic and
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the hypoxia-protective effects of EGFR inhibition whereas
mTOR inhibition only mimicked the hypoxia-protective effects.
Whether parallel rather than serial signal pathways are more
relevant for regulation of mTOR by EGFR through Akt, PKC or
both, thus remains to be determined. We have incorporated our
data and this new finding in a schematic drawing summarizing
the proposed functions of signalling molecules in glioblastoma
cells (Supplementary Fig. S6).
Even more striking than its lack of toxicity, mTOR antagonism
exerts powerful cytoprotective effects on hypoxic glioma cells (Figs
4B and C, 5G). mTOR is a master regulator of cellular energy
homeostasis and, under physiologic conditions, reduced mTOR
activity as a consequence of impaired nutrient availability enables
cells to survive by adapting metabolic processes (Peng et al.,
2002; Lee et al., 2007). Therefore, the hypoxia-protective effects
of mTOR inhibition should not come entirely unexpected. Our
results suggest that, in patients with malignant glioma, mTOR
inhibition may jeopardize the anti-tumour effects of both sponta-
neously occurring tumour hypoxia and hypoxia resulting from
anti-angiogenic therapies and may contribute to adverse outcome.
This hypothesis is based on studies demonstrating that sublethal
hypoxia is a major selective pressure driving and maintaining
genetic instability and a mutator phenotype which leads to the
selection of more aggressive tumour cell clones (Bristow and Hill,
2008) exhibiting therapy-resistance with reduced apoptotic
potential (Graeber et al., 1996) and increased invasive properties
(Pennacchietti et al., 2003). Hypoxia-protective effects of rapamy-
cin have also been observed in mouse LLC cells (Hamanaka et al.,
2005). The protection from hypoxia conferred by mTOR antago-
nism in conjunction with its lack of cytotoxicity may offer an
explanation for the disappointing results of clinical trials with
mTOR inhibitors for recurrent glioblastoma (Galanis et al.,
2005). It may be prudent to consider undesirable effects originat-
ing from alterations of cellular metabolism and energy homeostasis
for strategies targeting the EGFR-PI3K-Akt axis at any molecule,
upstream (Steinbach et al., 2004) or downstream of mTOR. The
validity of the assumption that the protection from hypoxia
conferred by the inhibition of EGFR and mTOR could result in clin-
ically relevant adverse effects is supported by recent data from
clinical trials combining EGFR inhibition with anti-angiogenetic
agents. Lassen et al. (ASCO Annual Meeting 2008, Abstract
#2056) presented data from a trial with erlotinib in combination
with bevacizumab and irinotecan in patients with progressive glio-
blastoma. Progression-free survival at 6 months in this one-armed
trial was at a disappointing level of 24%, compared with 48% in
the original study with bevacizumab and irinotecan (Wagner et al.,
ASCO Annual Meeting 2008, Abstract #2021). Overt antag-
onistic effects of the anti-EGFR antibody cetuximab were
demonstrated in a randomized phase III trial comparing bevacizu-
mab plus chemotherapy alone or combined with cetuximab
in patients with colon cancer (Tol et al., 2009). Notably, the
hypoxia-protective effect of EGFR inhibition in vitro is also detect-
able in colon carcinoma cells (S. Wolking et al., unpublished
results).
The complexity of the metabolic response of human malignant
glioma cells towards hypoxia is further illustrated by the dissocia-
tion of mTOR signalling and HIF-1 a. In non-transformed cells
and some tumour cell lines, mTOR induces HIF-1 a expression,
possibly via a posttranslational mechanism (Hudson et al., 2002).
Given that hypoxia suppresses mTOR signalling in malignant
glioma cells (Fig. 4A), this mechanism should result in reduced
expression of HIF-1 a. However, levels of HIF-1 a protein were
maintained in hypoxic mTORsh cells and cells exposed towards
rapamycin (Fig. 6E and F). One plausible explanation is that
hypoxic glioma cells are under selective pressure to maintain
HIF-1 a-dependent neoangiogenesis. Since HIF-1 a also exerts
metabolic effects important for the adaptation of tumour cells to
hypoxic conditions (Brahimi-Horn and Pouyssegur, 2007), the
capability of glioma cells to maintain HIF-1 a expression indepen-
dently of mTOR may also be important for the rapamycin-induced
protection from hypoxic cell death. HIF-1 a antagonistic strategies
therefore, potentially, could revert mTOR inhibition-dependent
resistance towards hypoxia.
Finally, mTOR inhibition may have valuable anti-tumour effects
that only become apparent in vivo. First, it has been shown that
rapamycin specifically sensitizes U87MG cell xenografts towards
radiotherapy while single layer cultures are not affected
(Eshleman et al., 2002). Notably, in that study rapamycin failed
to demonstrate in vivo growth-inhibitory effects in spite of the
known antiproliferative effects in vitro and the probable anti-
angiogenic effects, again suggesting mechanisms of rapamycin
resistance such as decreased susceptibility towards hypoxia.
Further, rapamycin also has anti-angiogenic properties, some of
which may be dependent on HIF-1 a (Del Bufalo et al., 2006;
Phung et al., 2007), whereas others may be dependent on
direct cytotoxic effects of rapamycin on human endothelial cells
(Barilli et al., 2008). These properties, in conjunction with the
strong antiproliferative effects of rapamycin and its low toxicity
as well as the successful clinical trials of mTOR-inhibition for
other tumour types, e.g. renal cell carcinoma, warrant further
studies of mTOR inhibition in malignant glioma patients.
A recently reported neoadjuvant trial of rapamycin treatment
prior to scheduled resection of recurrent glioblastoma with PTEN
loss followed by rapamycin maintenance therapy demonstrated
that nanomolar concentrations of rapamycin can be achieved in
glioblastoma (Cloughesy et al., 2008). The authors concluded that
rapamycin reduced proliferation in patients with evidence of
decreased RPS6 phosphorylation. The median time to progression
with adjuvant rapamycin therapy after surgery was only 99 days
in this molecular enriched population, although there was some
evidence of clinical activity. These results are well compatible with
our finding of growth inhibition as the principal anti-tumour effect
of rapamycin and suggest mechanisms of resistance towards
rapamycin other than insufficient tumour penetration.
Inhibition of mTOR may be most successful in the setting of
primary therapy in combination with radiotherapy. The risk for a
clinically relevant negative impact of the hypoxia-protective effects
of mTOR inhibition would plausibly be lowest for patients who
have undergone macroscopically complete resections of their
tumours that should minimize the occurrence of hypoxia. These
issues will be addressed in a forthcoming clinical study with the
non-immunosuppressant mTOR Inhibitor CCI-779 in combination
with radiotherapy versus radiotherapy alone in the primary
therapy of glioblastoma with unmethylated MGMT-promoter
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which will be conducted by the EORTC brain tumour group
(W. Wick, personal information).
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